{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-CD20+antibodies&page=5", "query": { "intervention": "Anti-CD20 antibodies", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 331, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-CD20+antibodies&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-CD20+antibodies&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T17:58:02.372Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00072449", "title": "Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2004-05", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072449" }, { "nct_id": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "High Grade B-Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 20, "start_date": "2026-12-08", "completion_date": "2031-10-08", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07714421" }, { "nct_id": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Myelodysplastic Syndrome" ], "interventions": [ { "name": "DS-1594b", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-25", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752163" }, { "nct_id": "NCT02871219", "title": "Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage II Grade 1 Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 1 Follicular Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Bulky Disease", "Fatigue", "Fever", "Grade 3a Follicular Lymphoma", "Night Sweats", "Splenomegaly", "Weight Loss" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2016-12-06", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02871219" }, { "nct_id": "NCT00003820", "title": "Rituximab in Treating Patients With Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Hodgkin Lymphoma (Category)", "Nodular Lymphocyte Predominant Hodgkin Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranjana Advani", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 39, "start_date": "1999-01", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2017-04-20", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 2, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003820" }, { "nct_id": "NCT04323956", "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Marginal Zone Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2020-06-15", "completion_date": "2028-05-16", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323956" }, { "nct_id": "NCT04673617", "title": "AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "AB-101", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artiva Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-03-29", "completion_date": "2025-10-06", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04673617" }, { "nct_id": "NCT02481310", "title": "Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Burkitt Lymphoma", "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma", "Diffuse Large B-Cell Lymphoma", "MYC Gene Mutation", "Plasmablastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2015-10-28", "completion_date": "2024-07", "has_results": true, "last_update_posted_date": "2022-02-21", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 5, "location_summary": "Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Medford", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02481310" }, { "nct_id": "NCT01829568", "title": "Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Grade 1 Follicular Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2013-06-26", "completion_date": "2027-06-06", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01829568" }, { "nct_id": "NCT01059786", "title": "Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hairy Cell Leukemia" ], "interventions": [ { "name": "Pentostatin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "Antihistamines", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" }, { "name": "Bronchodilators", "type": "DRUG" }, { "name": "Intravenous (IV) Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2010-07-01", "completion_date": "2031-06-30", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-09T17:58:02.372Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059786" } ] }